See more : PT Nusa Konstruksi Enjiniring Tbk (DGIK.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Treatment.Com International Inc. (TREIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Treatment.Com International Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- BioArctic AB (publ) (BIOA-B.ST) Income Statement Analysis – Financial Results
- Laser Tek Taiwan Co.,Ltd. (6207.TWO) Income Statement Analysis – Financial Results
- Topkey Corporation (4536.TW) Income Statement Analysis – Financial Results
- Gantan Beauty Industry Co., Ltd. (5935.T) Income Statement Analysis – Financial Results
- Sampo Oyj (SAMPOH.XD) Income Statement Analysis – Financial Results
Treatment.Com International Inc. (TREIF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.treatment.com
About Treatment.Com International Inc.
Treatment.Com International Inc. provides personalized health care information services in Canada. It also develops a mobile application for symptom assessment of users to address their health concerns, problems, and ongoing wellness management. The company offers a digital health app, an assessment tool which provides insights about health. In addition, the company provides medical education, medical clinic, and clinical advisor solutions; and offers healthcare information resource. Treatment.Com International Inc. was incorporated in 2018 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 377.28K | 656.40K | 326.85K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -377.28K | -656.40K | -326.85K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 354.49K | 590.20K | 2.19M | 1.30M | 326.02K | 20.55K | 31.96K |
| General & Administrative | 0.00 | 3.20M | 11.71M | 1.61M | 346.34K | 49.54K | 64.56K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.97M | 3.20M | 11.71M | 1.61M | 346.34K | 49.54K | 64.56K |
| Other Expenses | 0.00 | 0.00 | 9.83K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.33M | 3.79M | 13.90M | 2.91M | 672.36K | 70.08K | 96.52K |
| Cost & Expenses | 2.33M | 3.79M | 13.90M | 2.91M | 672.36K | 70.08K | 96.52K |
| Interest Income | 0.00 | 53.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 75.93K | 53.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 3.79M | 13.90M | 2.91M | 672.36K | 70.08K | 96.52K |
| EBITDA | -2.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.33M | -3.84M | -13.92M | -2.91M | -672.36K | -70.08K | -96.52K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.40M | 43.88K | 32.79K | 0.00 | -2.33M | 0.00 | 0.00 |
| Income Before Tax | -3.72M | -3.80M | -13.86M | -2.91M | -3.00M | -70.08K | -96.52K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -167.90K | -175.11K | -13.92M | -2.91M | 2.16M | -70.08K | -96.52K |
| Net Income | -3.72M | -3.80M | -13.86M | -2.91M | -3.00M | -70.08K | -96.52K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.26 | -0.57 | -2.14 | -0.45 | -0.47 | -0.01 | -0.02 |
| EPS Diluted | -0.26 | -0.57 | -2.14 | -0.45 | -0.47 | -0.01 | -0.02 |
| Weighted Avg Shares Out | 14.35M | 6.62M | 6.48M | 6.40M | 6.40M | 6.40M | 6.40M |
| Weighted Avg Shares Out (Dil) | 14.35M | 6.62M | 6.48M | 6.40M | 6.40M | 6.40M | 6.40M |
Treatment.com AI Announces Release of New Medical Education Suite (MES) and Update on the AI Assessment Symposium 1st November, 2024
● Treatment.com AI announces expanded and updated MES new releases ● Lead commercial participant at Global/North American Symposium on AI Assessment in Medical Education ● Further enhancements and solutions set for H2 2024 VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE...
REPEAT: TREATMENT.COM AI INC. CLOSES OVER-SUBSCRIBED NON- BROKERED PRIVATE PLACEMENT OF $1,954,074
Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States. Not for distribution to United States newswire services or for release...
TREATMENT.COM AI INC. CLOSES OVER-SUBSCRIBED NON- BROKERED PRIVATE PLACEMENT OF $1,954,074
Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States. Not for distribution to United States newswire services or for release...
Repeat: Treatment.com AI to Present at the 2024 Cantech Letter Conference in Toronto, ON
Treatment.com AI CEO, Dr. Essam Hamza, is to present live at 11:00 AM ET on Wednesday, October 9, 2024. VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”), a healthcare...
Treatment.com AI to Present at The 2024 Cantech Letter Conference in Toronto, ON
Treatment.com AI CEO, Dr. Essam Hamza, is to present live at 11:00 AM ET on Wednesday, October 9, 2024 Vancouver, British Columbia--(Newsfile Corp. - October 1, 2024) - Treatment.com AI Inc. (CSE: TRUE) (OTCQB: TREIF) (FSE: 939) ("Treatment"), a healthcare...
Repeat: Treatment.com AI Medical Education Corporate Update and Updates on Additional Marketing Engagements
VANCOUVER, British Columbia, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to provide marketing updates and a general corporate update on its focus on the utilization of AI within the...
Treatment.com AI Medical Education Corporate Update and Updates on Additional Marketing Engagements
VANCOUVER, British Columbia, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to provide marketing updates and a general corporate update on its focus on the utilization of AI within the...
Repeat: Treatment.com AI and SPRYT Join Forces to Improve Patient Access to Healthcare Services
VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with SPRYT Limited (“SPRYT”). Both innovative AI healthcare organizations, SPRYT and...
Treatment.com AI and SPRYT Join Forces to Improve Patient Access to Healthcare Services
VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with SPRYT Limited (“SPRYT”). Both innovative AI healthcare organizations, SPRYT and...
Repeat: Treatment.com AI and University of Edinburgh Join Forces to Transform Long-Term Care Services across the UK
VANCOUVER, British Columbia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with the University Court of the University of Edinburgh (“University of...
Source: https://incomestatements.info
Category: Stock Reports